Global Small Interfering RNA (siRNA) Therapeutics Market Insights Forecasts to 2033

• The Global Small Interfering RNA (siRNA) Therapeutics Market Size was Valued at USD 1.8 Billion in 2023
• The Market Size is Growing at a CAGR of 14.37% from 2023 to 2033
• The Worldwide Small Interfering RNA (siRNA) Therapeutics Market Size is Expected to Reach USD 6.89 Billion by 2033
• Europe is Expected to Grow the fastest during the forecast period.

The Global Small Interfering RNA (siRNA) Therapeutics Market Size is Anticipated to Exceed USD 6.89 Billion by 2033, Growing at a CAGR of 14.37% from 2023 to 2033.  The creation of novel medications is driving market expansion, which is assisted by rising expenditure in research programs by governments, private organizations, and pharmaceutical companies.  

Market Overview

Small interfering RNA (siRNA) therapy is a therapeutic approach that uses small synthetic RNA molecules to target pathogenic genes. Growing need for precision drug delivery, new delivery methods and better molecular knowledge of disease-causing agents are driving the growth of siRNA therapies in the market.  Furthermore, the growing prevalence of continual illnesses creates brilliant potentialities for growing and commercializing drugs based totally on short-interfering RNA. Moreover, the small interfering RNA (siRNA) treatment plans marketplace is presently gaining traction, supported via more funding and technological breakthroughs. Notably, Boehringer Ingelheim has invested more than $2 billion to explore siRNA drug treatments focused on metabolic-related steatohepatitis (MASH), reflecting the improved interest of big pharmaceutical organizations in RNA-based remedies. The international small interfering RNA (siRNA) therapeutics marketplace is increasing unexpectedly, because of a growth in the superiority of genetic problems and advances in targeted shipping strategies.

Opportunities in the Global siRNA Therapeutics Market

The global small interfering RNA (siRNA) therapeutics market presents substantial prospects, due to the rising prevalence of genetic illnesses and the demand for precision medicine. Innovations in delivery technologies improve the efficacy of these medicines, while biotechnology alliances speed development. Furthermore, the increased acceptability of personalized medicine and potential growth in emerging economies provide up new avenues for siRNA applications, preparing this industry for considerable rise.

Report Coverage

This research report categorizes the global small interfering RNA (siRNA) therapeutics market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global small interfering RNA (siRNA) therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global small interfering RNA (siRNA) Therapeutics market.  

Driving Factors

The global small interfering RNA (siRNA) therapeutics market is expanding due to rising demand for targeted medicines, advances in RNA delivery methods, and increased funding for RNA-based drug development. Silencing individual genes in siRNA therapies allows for more precise treatment of hereditary and uncommon disorders. Expanding applications in oncology, cardiovascular disease, and viral infections, together with regulatory backing and successful clinical studies, are driving market growth. The increasing frequency of chronic diseases, burgeoning biopharmaceutical collaborations, and customized medicine trends are driving the worldwide siRNA therapeutics market. Increased investment in R&D and developing medicines for previously untreatable illnesses also helps to drive market expansion.

Restraining Factors

The difficulty of effective delivery methods is to maintain stability while avoiding immunological reactions. High development costs, regulatory constraints, and low knowledge of RNA-based medicines further hamper market expansion, especially in nations with less developed healthcare infrastructure.

Market Segmentation

The global small interfering RNA (siRNA) therapeutics market share is classified into delivery, indication and RoA.

• The lipid nanoparticles (LNPs) segment is expected to hold the largest share of the global small interfering RNA (siRNA) therapeutics market during the forecast period.                   

Based on delivery, the global small interfering RNA (siRNA) therapeutics market is categorized as lipid nanoparticles (LNPs), and conjugates. Among these, the lipid nanoparticles (LNPs) segment is expected to hold the largest share of the global small interfering RNA (siRNA) therapeutics market during the forecast period.  Growth is attributed to their superior capacity to increase siRNA stability, defend against degradation, and improve targeted distribution. LNPs provide effective encapsulation, ensuring precise gene silencing, hence increasing their usage in clinical applications. Moreover, their flexibility to a variety of diseases, including cancer and uncommon genetic disorders, boosts projected market expansion.

• The primary hyperoxaluria type 1 segment is expected to grow at the fastest CAGR during the forecast period.        

Based on the indication, the global small interfering RNA (siRNA) therapeutics market is categorized as hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, primary hypercholesterolemia, and others. Among these, the primary hyperoxaluria type 1 segment is expected to grow at the fastest CAGR during the forecast period. This is due to the recent approval of lumasiran, a PH1-specific siRNA treatment, and also increased awareness of the disease. Furthermore, the increased focus on treating rare genetic disorders, together with expanded clinical trials and innovative treatment advancements, drives significant market expansion in this area.

• The subcutaneous segment is expected to hold the largest share of the global small interfering RNA (siRNA) therapeutics market during the forecast period.                   

Based on RoA, the global small interfering RNA (siRNA) therapeutics market is categorized as intravenous (IV), subcutaneous. Among these, the subcutaneous segment is expected to hold the largest share of the global small interfering RNA (siRNA) therapeutics market during the forecast period. This is due to the simplicity of self-administration, increased patient compliance, and less need for clinician visits. The subcutaneous distribution also improves patient accessibility and has been extensively used in siRNA therapy for illnesses such as inherited transthyretin-mediated amyloidosis and primary hyperoxaluria type 1, which has led to its market dominance.

Regional Segment Analysis of the Global Small Interfering RNA (siRNA) Therapeutics Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is projected to hold the largest share of the global small interfering RNA (siRNA) therapeutics market over the forecast period.

North America is projected to hold the largest share of the global Small Interfering RNA (siRNA) Therapeutics market over the forecast period. This expansion is driven by major investments in biotechnology and pharmaceuticals, as well as a well-established healthcare infrastructure. The region has major academic and research facilities, which stimulate innovation and clinical trials in siRNA therapeutics. Furthermore, rising awareness of genetic illnesses and the need for customized medicine expand market potential in North America, cementing its leadership position. Furthermore, the United States leads in the adoption of novel siRNA therapeutics, reinforcing North America's position as the largest market.

Europe is expected to grow at the fastest CAGR growth of the global small interfering RNA (siRNA) therapeutics market during the forecast period. The region benefits from a robust regulatory environment that encourages the discovery of novel therapeutics, and also an increasing emphasis on customized medicine. Market growth is also being driven by higher expenditures in research & development, along with the rising prevalence of genetic disorders. Furthermore, collaboration between research institutions and pharmaceutical businesses in Europe promotes the growth of siRNA technologies, strengthening the region's competitiveness.  

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global small interfering RNA (siRNA) therapeutics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Alnylam
• Quark Pharmaceuticals
• Dicerna Pharmaceuticals
• Arrowhead Pharmaceuticals
• Novartis
• Novo Nordisk
• Johnson & Johnson company
• GSK
• Silence Therapeutics
• Silenseed Ltd
• Sylentis, S.A.
• Sanofi Genzyme
• Aro Biotherapeutics
• Others

Key Market Developments

• In May 2024, Wave Life Sciences revealed continuous success in their collaboration with GSK, including significant advances in siRNA and RNA editing. Wave collaborated with GSK to identify its first two initiatives for future development after successfully verifying their targets. These applications made use of Wave's sophisticated GalNAc-siRNA format, which represents the next generation of hepatology technology.

• In May 2024, A clinical trial led by Mount Sinai researchers found that small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism significantly reduced levels of different types of cholesterol and triglycerides in people with mixed hyperlipidemia, a condition in which fats accumulate in the blood.  

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global small interfering RNA (siRNA) therapeutics market based on the below-mentioned segments: 

Global Small Interfering RNA (siRNA) Therapeutics Market, By Delivery

• Lipid Nanoparticles (LNPs)
• Conjugates

Global Small Interfering RNA (siRNA) Therapeutics Market, By Indication

• Hereditary Transthyretin-mediated Amyloidosis
• Acute Hepatic Porphyria
• Primary Hyperoxaluria Type 1
• Primary Hypercholesterolemia
• Others

Global Small Interfering RNA (siRNA) Therapeutics Market, RoA

• Intravenous (IV)
• Subcutaneous

Global Small Interfering RNA (siRNA) Therapeutics Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa